Last reviewed · How we verify

NCT03953547: RAP

Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization

Completed Last updated 21 May 2019
What this trial tests

trial in Vascular Diseases in 88 participants. Completed in 31 March 2018.

Timeline
1 January 2018
Primary endpoint
1 March 2018
31 March 2018

Quick facts

Lead sponsorFondation Hôpital Saint-Joseph
StatusCompleted
Study typeOBSERVATIONAL
Enrollment88
Start date1 January 2018
Primary completion1 March 2018
Estimated completion31 March 2018
Sites1 location across France

Conditions studied

Sponsor

Fondation Hôpital Saint-Joseph — full company profile →

Who can join

18 and older, any sex, with Vascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In coronary pathology, persistent platelet hyperresponsiveness under antiplatelet therapy, which is often referred to as "antiplatelet resistance," is predictive of increased risk of thrombotic recurrence as well as hyper-Inhibition of this aggregation may be predictive of a hemorrhagic risk. But no study has shown that the adaptation of treatment based on platelet aggregation tests has a benefit: the management of antiplatelet treatments through the search for antiplatelet resistance (APR) is not recommended by the European Society of Cardiology (ESC) in the context of coronary angioplasty (IIIA), while this is a common practice in neurovascular pathology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vascular Diseases

Currently open trials in the same condition.

Other Fondation Hôpital Saint-Joseph trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03953547.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing